{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T10:29:43Z","timestamp":1793788183573,"version":"4.6.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T00:00:00Z","timestamp":1591833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T00:00:00Z","timestamp":1591833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Amgen Australia","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Celgene Australia","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Janssen Australia","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Multiple Myeloma (MM) is a cancer characterised by the proliferation of malignant plasma cells in the bone marrow. This study examined the treatment preferences of people living with MM compared to the treatment preferences of other groups involved in treatment decision making, including carers, as well as physicians and nurses who treat people living with MM in Australia.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Data were collected using discrete choice experiments (DCEs) through an online survey. The DCEs presented participants with a traditional treatment generic choice experiment (e.g., treatment A vs treatment B), focusing on the clinical benefits of treatments and the associated risks. The attributes and levels of the attributes were selected based on previous research, literature review, qualitative research and expert opinion. The DCE data were modelled using a Latent Class Model (LCM).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The model revealed significant heterogeneity in preferences for treatment attributes. In particular, overall survival, remission period and annual out of pocket cost were the attributes with the most variation. In comparison to people living with MM, carers were less cost-sensitive and more concerned with quality of life (remission period). Physicians and nurses were generally more concerned with overall survival and more cost sensitive than people living with MM.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This study demonstrated that not all people living with MM valued the same treatment attributes equally. Further, not all groups involved in MM treatment decision making had preference alignment on all treatment attributes. This has important implications for healthcare policy decisions and shared decision making. Results from this study could be used to guide decisions around the value of new MM medicines or the medical plan surrounding the needs of those living with MM, as well as those caring for them.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12885-020-07018-6","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T18:03:52Z","timestamp":1591898632000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Alignment of preferences in the treatment of multiple myeloma \u2013 a discrete choice experiment of patient, carer, physician, and nurse preferences"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5221-0067","authenticated-orcid":false,"given":"Simon J.","family":"Fifer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerrie-Anne","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Lybrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie J.","family":"Axford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Roach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,11]]},"reference":[{"issue":"11","key":"7018_CR1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K. Multiple Myeloma. N Engl J Med. 2011;364(11):1046\u201360.","journal-title":"N Engl J Med"},{"issue":"9","key":"7018_CR2","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","volume":"4","author":"AJ Cowan","year":"2018","unstructured":"Cowan AJ, Allen C, Barac A, et al. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol. 2018;4(9):1221\u20137.","journal-title":"JAMA Oncol"},{"key":"7018_CR3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13045-016-0282-1","volume":"9","author":"L Naymagon","year":"2016","unstructured":"Naymagon L, Abdul-Hay M. Novel agents in the treatment of multiple myeloma: a review about the future. J Hematol Oncol. 2016;9:52.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"7018_CR4","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/17474086.2017.1326814","volume":"10","author":"S Genadieva Stavric","year":"2017","unstructured":"Genadieva Stavric S, Bonello F, Bringhen S, Boccadoro M, Larocca A. How is patient care for multiple myeloma advancing? Expert Rev Hematol. 2017;10(6):551\u201361.","journal-title":"Expert Rev Hematol"},{"key":"7018_CR5","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.hemonc.2017.05.005","volume":"10","author":"P Hari","year":"2017","unstructured":"Hari P. Recent advances in understanding multiple myeloma. Hematol Oncol Stem Cell Ther. 2017;10:267\u201371.","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"7018_CR6","first-page":"4","volume":"2007","author":"JF Bridges","year":"2007","unstructured":"Bridges JF, Onukwugha E, Johnson FR, Hauber AB. Patient preference methods \u2013 a patient centered evaluation paradigm. ISPOR Connect. 2007;2007:4\u20137.","journal-title":"ISPOR Connect"},{"key":"7018_CR7","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1748-5908-8-64","volume":"8","author":"CD Dirksen","year":"2013","unstructured":"Dirksen CD, Utens CMA, Joore MA, van Barneveld TA, Boer B, Dreesens DHH, van Laarhoven H, Smit C, Stiggelbout AM, van der Weijden T. Integrating evidence on patient preferences in healthcare policy decisions: protocol of the patient-VIP study. Implement Sci. 2013;8:64.","journal-title":"Implement Sci"},{"key":"7018_CR8","volume-title":"Incorporating quantitative patient preference data into healthcare decision making processes: is HTA falling behind? The Patient - Patient-Centered Outcomes Research","author":"DJ Mott","year":"2018","unstructured":"Mott DJ. Incorporating quantitative patient preference data into healthcare decision making processes: is HTA falling behind? The Patient - Patient-Centered Outcomes Research; 2018."},{"issue":"7414","key":"7018_CR9","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1136\/bmj.327.7414.542","volume":"327","author":"RE Say","year":"2003","unstructured":"Say RE, Thomson R. The importance of patient preferences in treatment decisions\u2014challenges for doctors. BMJ. 2003;327(7414):542\u20135.","journal-title":"BMJ"},{"issue":"3","key":"7018_CR10","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.pec.2008.07.054","volume":"73","author":"A Barratt","year":"2008","unstructured":"Barratt A. Evidence based medicine and shared decision making: the challenge of getting both evidence and preferences into health care. Patient Educ Couns. 2008;73(3):407\u201312.","journal-title":"Patient Educ Couns"},{"key":"7018_CR11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1089\/1093507042264827","volume":"7","author":"J Hopkins","year":"2004","unstructured":"Hopkins J, American Healthways. Defining the patient-physician relationship for the 21st century. Dis Manag. 2004;7:161\u201379.","journal-title":"Dis Manag"},{"key":"7018_CR12","first-page":"10","volume":"5","author":"AC M\u00fchlbacher","year":"2008","unstructured":"M\u00fchlbacher AC, Lincke H-J, N\u00fcbling M. Evaluating patients\u2019 preferences for multiple myeloma therapy, a Discrete-Choice-Experiment. GMS Psycho Soc Med. 2008;5:10.","journal-title":"GMS Psycho Soc Med"},{"issue":"3","key":"7018_CR13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10198-010-0218-6","volume":"12","author":"AC M\u00fchlbacher","year":"2011","unstructured":"M\u00fchlbacher AC, N\u00fcbling M. Analysis of physicians\u2019 perspectives versus patients\u2019 preferences: direct assessment and discrete choice experiments in the therapy of multiple myeloma. Eur J Health Econ. 2011;12(3):193\u2013203.","journal-title":"Eur J Health Econ"},{"issue":"2","key":"7018_CR14","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.clinthera.2017.12.012","volume":"40","author":"T Bolt","year":"2018","unstructured":"Bolt T, Mahlich J, Nakamura Y, Nakayama M. Hematologists\u2019 preferences for first-line therapy characteristics for multiple myeloma in japan: attribute rating and discrete choice experiment. Clin Ther. 2018;40(2):296\u2013308.e292.","journal-title":"Clin Ther"},{"issue":"34","key":"7018_CR15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1037\/h0070288","volume":"4","author":"LL Thurstone","year":"1927","unstructured":"Thurstone LL. A law of comparative judgment. Psychol Rev. 1927;4(34):273\u201386.","journal-title":"Psychol Rev"},{"key":"7018_CR16","volume-title":"Conditional Logit analysis of qualitative choice analysis","author":"DL McFadden","year":"1974","unstructured":"McFadden DL. Conditional Logit analysis of qualitative choice analysis. New York: Academic; 1974."},{"key":"7018_CR17","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1086\/259131","volume":"74","author":"KJ Lancaster","year":"1966","unstructured":"Lancaster KJ. A new approach to consumer theory. J Polit Econ. 1966;74:132\u201357.","journal-title":"J Polit Econ"},{"issue":"1982","key":"7018_CR18","first-page":"11","volume":"890","author":"JJ Louviere","year":"1982","unstructured":"Louviere JJ, Hensher DA. On the design and analysis of simulated choice or allocation experiments in travel choice modelling. Transp Res Rec. 1982;890(1982):11\u20137.","journal-title":"Transp Res Rec"},{"issue":"4","key":"7018_CR19","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1177\/002224378302000403","volume":"20","author":"JJ Louviere","year":"1983","unstructured":"Louviere JJ, Woodworth G. Design and analysis of simulated consumer choice or allocation experiments: an approach based on aggregate data. J Mark Res. 1983;20(4):350\u201367.","journal-title":"J Mark Res"},{"issue":"4","key":"7018_CR20","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2165\/11539650-000000000-00000","volume":"3","author":"D Marshall","year":"2010","unstructured":"Marshall D, Bridges JF, Hauber B, Cameron R, Donnalley L, Fyie K, Johnson FR. Conjoint analysis applications in health - how are studies being designed and reported? Patient. 2010;3(4):249\u201356.","journal-title":"Patient"},{"issue":"4","key":"7018_CR21","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2165\/1312067-200801040-00009","volume":"1","author":"JFP Bridges","year":"2008","unstructured":"Bridges JFP, Kinter ET, Kidane L, Heinzen RR, McCormick C. Things are looking up since we started listening to patients. Patient. 2008;1(4):273\u201382.","journal-title":"Patient"},{"issue":"8","key":"7018_CR22","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00019053-200826080-00004","volume":"26","author":"E Lancsar","year":"2008","unstructured":"Lancsar E, Louviere J. Conducting discrete choice experiments to inform healthcare decision making. PharmacoEconomics. 2008;26(8):661\u201377.","journal-title":"PharmacoEconomics"},{"issue":"1","key":"7018_CR23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/1477-7525-11-173","volume":"11","author":"RJ Hoefman","year":"2013","unstructured":"Hoefman RJ, van Exel J, Brouwer WB. Measuring the impact of caregiving on informal carers: a construct validation study of the CarerQol instrument. Health Qual Life Outcomes. 2013;11(1):173.","journal-title":"Health Qual Life Outcomes"},{"issue":"9","key":"7018_CR24","doi-asserted-by":"crossref","first-page":"A451","DOI":"10.1016\/j.jval.2017.08.299","volume":"20","author":"S Bauer","year":"2017","unstructured":"Bauer S, Mueller S, Ratsch B, Pitura S, Probst L, van Eickels D, Wilke T. Patient preferences regarding treatment options for relapsed refractory multiple myeloma (RRMM). Value Health. 2017;20(9):A451.","journal-title":"Value Health"},{"issue":"2","key":"7018_CR25","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.14213","volume":"175","author":"K Yong","year":"2016","unstructured":"Yong K, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S, Safaei R, Karlin L, Mateos M-V, Raab MS, et al. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol. 2016;175(2):252\u201364.","journal-title":"Br J Haematol"},{"issue":"89","key":"7018_CR26","first-page":"175","volume":"3","author":"AC M\u00fchlbacher","year":"2011","unstructured":"M\u00fchlbacher AC, N\u00fcbling M. Analysis of physicians\u2019 perspectives versus patients\u2019 preferences: direct assessment and discrete choice experiments in the therapy of multiple myeloma. Eur J Health Econ. 2011;3(89):175\u201380.","journal-title":"Eur J Health Econ"},{"issue":"4","key":"7018_CR27","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"JFP Bridges","year":"2011","unstructured":"Bridges JFP, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, Johnson FR, Mauskopf J. Conjoint analysis applications in health\u2014a checklist: A report of the ISPOR good research practices for conjoint analysis task force. Value Health. 2011;14(4):403\u201313.","journal-title":"Value Health"},{"issue":"5","key":"7018_CR28","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1080\/01441640902827623","volume":"29","author":"JM Rose","year":"2009","unstructured":"Rose JM, Bliemer MC. Constructing efficient states choice experimental designs. Trans Rev. 2009;29(5):587\u2013617.","journal-title":"Trans Rev"},{"key":"7018_CR29","doi-asserted-by":"publisher","unstructured":"Hensher DA, Rose J, Greene W. Applied choice analysis. Cambridge: Cambridge University Press; 2015. https:\/\/doi.org\/10.1017\/CBO9781316136232. https:\/\/www.cambridge.org\/core\/books\/applied-choice-analysis\/D409294010B38CBA138AB110B26AC6B7.","DOI":"10.1017\/CBO9781316136232"},{"issue":"3","key":"7018_CR30","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40271-019-00360-3","volume":"12","author":"JM Gonzalez","year":"2019","unstructured":"Gonzalez JM. A guide to measuring and interpreting attribute importance. Patient. 2019;12(3):287\u201395.","journal-title":"Patient"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07018-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-07018-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07018-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T23:31:07Z","timestamp":1623367867000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07018-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,11]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7018"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07018-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,11]]},"assertion":[{"value":"5 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Bellberry Limited Human Research Ethics Committee, Australia. All participants provided informed written consent prior to participating in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SL is an employee of Amgen Australia. KAH, SJF and LJA have conducted research funded by Amgen Australia, AstraZeneca Australia, Celgene Australia, Janssen Australia, Roche Australia and Sanofi Japan in the last 12\u2009months.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"546"}}